|
US2021015906A1
|
|
Enzyme replacement therapy for mucopolysaccharidosis iiid
|
|
US2020155536A1
|
|
P97 inhibitors for treating cancer and neurodegenerative disorders
|
|
WO2020061084A1
|
|
Target-primed macrophages and therapeutic uses thereof
|
|
EP3790625A1
|
|
Systems, apparatus, and methods for documenting code blue scenarios
|
|
EP3505181A1
|
|
Preparation of enzyme replacement therapy for mucopolysaccharidosis iiid
|
|
WO2018209127A1
|
|
Antimicrobial peptides with alpha-core helices
|
|
WO2018209129A1
|
|
Antimicrobial type-ii bacteriocins
|
|
US2018250519A1
|
|
Systems, apparatus, and methods for documenting code blue scenarios
|
|
US2020121444A1
|
|
Stent grafts, mandrels, and methods of usng same
|
|
EP3552620A1
|
|
Methods of treatment for candida auris infections
|
|
CN112203684A
|
|
Treatment of candida otic infections
|
|
US2021093587A1
|
|
Methods and Compositions for Modulating Beta-Amyloid/Alpha7-nAChR Interactions
|
|
US2018263941A1
|
|
Methods of modulating miRNA levels and compositions for use in the same
|
|
US2018353570A1
|
|
Methods for reducing cardiotoxicity from chemotherapy by administering humanin analog compositions
|
|
US2018110451A1
|
|
Apparatus, systems, and methods for detecting congenital heart disease in newborns
|
|
US2019265238A1
|
|
Fungal toxins and methods related to the same
|
|
US2017347931A1
|
|
Foot pulse oximeter for screening congenital heart disease before newborn discharge
|
|
WO2018022916A1
|
|
Integrated fiber optic sensor umbilical catheter
|
|
EP3452041A1
|
|
Compositions and methods for administering ppar agonists, surfactant peptides and phospholipids
|
|
CN108472372A
|
|
In conjunction with the antibody conjugate and application thereof of acinetobacter calcoaceticus
|
